A focused portfolio of
biosimilar antibodies.

BioXpress’ biosimilar trastuzumab (biosimilar to Herceptin) is a monoclonal antibody therapy used to treat HER2-positive breast and stomach cancers by slowing the growth of and killing cancer cells.

BioXpress’ biosimilar alemtuzumab (biosimilar to Lemtrada) is a humanised monoclonal antibody targeting CD52, a protein found on T and B lymphocytes. It causes rapid, long-lasting depletion of these immune cells and is used to treat active relapsing-remitting multiple sclerosis (RRMS) and B-cell chronic lymphocytic leukaemia (B-CLL).

BioXpress’ biosimilar bevacizumab (biosimilar to Avastin) is a monoclonal antibody therapy and anti-angiogenesis agent that treats various cancers by essentially starving tumours of the blood supply needed for growth.

BioXpress’ biosimilar adalimumab (biosimilar to Humira) is a biologic medication that reduces inflammation and suppresses an overactive immune system by inhibiting tumour necrosis factor-alpha. It is used to treat autoimmune conditions including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, ankylosing spondylitis and juvenile idiopathic arthritis.

BioXpress’ biosimilar rituximab (biosimilar to Rituxan) is a monoclonal antibody drug that targets and destroys CD20-positive B cells to treat certain blood cancers, autoimmune diseases and chronic inflammation.

BioXpress’ biosimilar daratumumab (biosimilar to Darzalex) is a monoclonal antibody therapy used to treat multiple myeloma and AL amyloidosis by binding to the CD38 protein on cancer cells, marking them for destruction by the immune system.

BioXpress’ biosimilar emicizumab (biosimilar to Hemlibra) is a bispecific monoclonal antibody used to prevent or reduce bleeding frequency in patients with haemophilia A, with or without factor VIII inhibitors.

BioXpress’ biosimilar pembrolizumab (biosimilar to Keytruda) is a monoclonal antibody widely used in immunotherapy as a PD-1 inhibitor that helps the immune system fight cancer. It is approved to treat many cancers, including melanoma, non-small cell lung cancer, breast cancer and Hodgkin lymphoma.

BioXpress’ biosimilar nivolumab (biosimilar to Opdivo) is a monoclonal antibody used to treat various advanced cancers, including melanoma, non-small cell lung cancer and renal cell carcinoma. It functions as a PD-1 checkpoint inhibitor, allowing the immune system to recognise and destroy cancer cells.